dapivirine + clotrimazole

Dapivirine + clotrimazole is a combination of two pharmaceutical agents used in the context of vaginal administration. Dapivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that acts as a microbicide to prevent HIV-1 infection by inhibiting HIV-1 replication in susceptible cells, primarily through topical delivery via the dapivirine vaginal ring[5][8]. Clotrimazole is an imidazole antifungal agent that treats vaginal yeast infections by inhibiting ergosterol biosynthesis, thereby disrupting fungal cell membrane integrity and function[2][6]. Clinical studies have evaluated the pharmacokinetics and safety of co-administering these drugs, showing no clinically relevant drug-drug interactions or significant changes in systemic exposure for either agent when used together[3][4]. The combination may be considered for women at risk of both HIV infection and vulvovaginal candidiasis.